Under GILEAD licenses generic Sofosbuvir is available in India since March 2015, this is the latest information regarding availability and price of generic Sofosbuvir drugs in India as on 15 June 2015..see the full list
June 16, 2015admin
26 May 2015 Indonesia AIDS Coalition (IAC) wrote a letter to BPOM (Indonesian Food and Drugs Authority) to expedite the registration process of DAA medicines in Indonesian market. Click to see the full letter in Bahasa Indonesia or English
June 4, 2015admin
Source: http://www.msfaccess.org MSF is in the process of starting to treat people who are living with hepatitis C virus (HCV) in at least nine countries, and therefore is in need of affordable access to direct acting antiviral (DAA) treatments, including those marketed by Gilead Sciences (Gilead) and Bristol-Myers Squibb (BMS). There are legal ...
May 19, 2015admin
Under GILEAD licenses generic Sofosbuvir is available in India since March 2015, this is the latest information regarding availability and price of generic Sofosbuvir drugs in India as on 18 May 2015..read full document
May 18, 2015admin
2nd May 2015 - Stepping up efforts to counter patents on life-saving medicines, three civil society groups working to increase access to affordable, life-saving Hepatitis C (HCV) medicines, have challenged Bristol-Myers Squibb (BMS’) pending patent application on Daclatasvir before the Delhi Patent Office. The pre-grant opposition filed by Hepatitis Coalition, Nagaland ...
May 6, 2015admin
March 25, 2015 - A letter from Civil Society Organizations in Asia and Eastern Europe to the Global Fund Board in advance of its Thirty-Third Meeting regarding the role of the Global Fund in providing and scaling up access to hepatitis C treatment…read full letter
March 2015 – WHO published the updated working paper on Sofosbuvir as key medicine for Hep C treatment and describes the relevant patents for Sofosbuvir and providing data where these patents have been filed or granted…read more
WHO working paper to identify relevant patents for Daclatasvir and providing data where these patents have been filed or granted...read more
Regional advocacy platform for access to Hep C treatment in Asia Pacific wrote to The Secretary of the 20th Expert Committee on the Selection and Use of Essential Medicines supporting MSF’s application to include Daclatasvir in the Model List of Essential Medicines of the World Health Organisation (WHO)...read full letter
April 2, 2015admin